Lexaria Bioscience Corp Stock Current Valuation
| LEXXW Stock | USD 0.78 0.03 4.00% |
Valuation analysis of Lexaria Bioscience Corp helps investors to measure Lexaria Bioscience's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to climb to 395.77 in 2024. Enterprise Value Multiple is likely to climb to 395.77 in 2024.
Overvalued
Today
Please note that Lexaria Bioscience's price fluctuation is out of control at this time. Calculation of the real value of Lexaria Bioscience Corp is based on 3 months time horizon. Increasing Lexaria Bioscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lexaria stock is determined by what a typical buyer is willing to pay for full or partial control of Lexaria Bioscience Corp. Since Lexaria Bioscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lexaria Stock. However, Lexaria Bioscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.78 | Real 0.68 | Hype 0.75 | Naive 0.8 |
The intrinsic value of Lexaria Bioscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lexaria Bioscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lexaria Bioscience Corp helps investors to forecast how Lexaria stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lexaria Bioscience more accurately as focusing exclusively on Lexaria Bioscience's fundamentals will not take into account other important factors: Lexaria Bioscience Corp Company Current Valuation Analysis
Lexaria Bioscience's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Lexaria Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Lexaria Bioscience is extremely important. It helps to project a fair market value of Lexaria Stock properly, considering its historical fundamentals such as Current Valuation. Since Lexaria Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexaria Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexaria Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Lexaria Current Valuation Historical Pattern
Today, most investors in Lexaria Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexaria Bioscience's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lexaria Bioscience current valuation as a starting point in their analysis.
Lexaria Bioscience Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Lexaria Bioscience Corp has a Current Valuation of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Lexaria Bioscience Corp is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 68.84 Million. Lexaria Bioscience adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.Lexaria Bioscience Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lexaria Bioscience from analyzing Lexaria Bioscience's financial statements. These drivers represent accounts that assess Lexaria Bioscience's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lexaria Bioscience's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 12.4M | 27.3M | 17.4M | 6.9M | 48.4M | 115.2M | |
| Enterprise Value | 11.3M | 16.5M | 11.7M | 5.8M | 42.1M | 116.4M |
Lexaria Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (20.75) % | ||||
| Number Of Shares Shorted | 3.05 K | ||||
| Revenue | 464.28 K | ||||
| EBITDA | (5.75 M) | ||||
| Net Income | (5.81 M) | ||||
| Cash And Equivalents | 1.31 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 137.37 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 8.52 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (4.96 M) | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 33.79 M | ||||
| Total Asset | 8.87 M | ||||
| Retained Earnings | (51.56 M) | ||||
| Working Capital | 1.93 M | ||||
| Net Asset | 8.87 M |
About Lexaria Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexaria Bioscience Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.